Context Therapeutics Inc. Annual Operating Income (Loss) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Context Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2023.
  • Context Therapeutics Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$18.7M, a 203% decline year-over-year.
  • Context Therapeutics Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$32.5M, a 47.8% decline year-over-year.
  • Context Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$25.1M, a 63% decline from 2022.
  • Context Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$15.4M, a 46.1% decline from 2021.
  • Context Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$10.5M, a 309% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$25.1M -$9.69M -63% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-21
2022 -$15.4M -$4.86M -46.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-21
2021 -$10.5M -$7.95M -309% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-22
2020 -$2.57M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.